BBIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BBIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.
BridgeBio Pharma's Days Sales Outstanding for the
three
months ended in Mar. 2024 was 0.
BridgeBio Pharma's Days Inventory for the
three
months ended in Mar. 2024 was 0.
BridgeBio Pharma's Days Payable for the
three
months ended in Mar. 2024 was 1173.66.
Therefore, BridgeBio Pharma's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2024 was -1,173.66.
The historical data trend for BridgeBio Pharma's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BridgeBio Pharma Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Cash Conversion Cycle | Get a 7-Day Free Trial | -1,632.35 | - | -1,220.71 | -1,245.83 | -1,657.35 |
BridgeBio Pharma Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cash Conversion Cycle | Get a 7-Day Free Trial | -1,095.70 | -605.54 | -636.77 | -1,154.13 | -1,173.66 |
For the Biotechnology subindustry, BridgeBio Pharma's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where BridgeBio Pharma's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
BridgeBio Pharma's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as
Cash Conversion Cycle | = | Days Sales Outstanding | + | Days Inventory | - | Days Payable |
= | 0 | + | 0 | - | 1657.35 | |
= | -1,657.35 |
BridgeBio Pharma's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:
Cash Conversion Cycle | = | Days Sales Outstanding | + | Days Inventory | - | Days Payable |
= | 0 | + | 0 | - | 1173.66 | |
= | -1,173.66 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BridgeBio Pharma (NAS:BBIO) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Thank you for viewing the detailed overview of BridgeBio Pharma's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.
Hannah Valantine | director | 1305 O'BRIEN DRIVE, MENLO PARK CA 94025 |
Frank Mccormick | officer: Chairman of Oncology | C/O UCSF, 1450 3RD STREET, RM HD-371, SAN FRANCISCO CA 941439001 |
Randal W Scott | director | 171 MAIN STREET #225, LOS ALTOS CA 94022 |
Neil Kumar | director, officer: See Remarks | C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304 |
Brian C Stephenson | officer: See Remarks | 3160 PORTER DR, STE 250, PALO ALTO CA 94304 |
Viking Global Opportunities Parent Gp Llc | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Viking Global Investors Lp | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Douglas A. Dachille | director | 175 WATER STREET, NEW YORK NY 10038 |
Andrew Lo | director | C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142 |
Ronald J Daniels | director | C/O MOORE CORPORATION LIMITED, ONE CANTERBURY GREEN, STAMFORD CT 06901 |
Fred Hassan | director | C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487 |
James C Momtazee | director | 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025 |
Brent L Saunders | director | 2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033 |
Andrea Ellis | director | C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301 |
Richard H Scheller | director, officer: See Remarks | C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990 |
From GuruFocus
By Business Wire • 10-03-2023
By Marketwired • 07-18-2023
By Marketwired • 09-25-2023
By Marketwired • 08-03-2023
By sperokesalga sperokesalga • 06-20-2023
By Marketwired • 09-08-2023
By Marketwired • 07-31-2023
By Marketwired • 10-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.